Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Sucampo Pharmaceuticals ($SCMP) stock touched $17.20 during its Tuesday trading session. The stock finally closed at $17.20. It is trading close to its 52 weeks high of $18.75. The stock is currently showing strong momentum, having gained over 47% in the past one month.
Sucampo Pharmaceuticals stock is mainly buoyed by the announcement of strong quarter three numbers and robust guidance. The company reported its quarterly revenue at $57.9 million, up 73% on year over year basis. Its earnings for the quarter stood at $0.19 per diluted share, up from $0.16 per diluted share income it had reported for the corresponding period of the previous year.

Celldex Therapeutics Inc. ($CLDX) announced the completion of its previously reported acquisition of Kolltan Pharmaceuticals Inc., which is a privately held company. It deals with discovery and development of novel, antibody-based drugs targeting receptor tyrosine kinases (RTKs).
Celldex CEO Anthony Marucci said that the acquisition will help in boosting the company’s product portfolio. The company had recently reported positive pre-clinical data on its new cancer candidate, CDX-1140. It is a fully human antibody that targets CD40 and demonstrated potent agonist activity. The company expects the treatment to be a valuable addition to its immunotherapy pipeline.

 

• Audentes Therapeutics ($BOLD) reported the successful deployment of its large-scale cGMP production runs at its new state-of-the-art manufacturing facility. The company is now in position to meet the material requirements for the clinical development of its pipeline. The company currently has two major candidates, AT132 for X-Linked Myotubular Myopathy and AT342 for Crigler-Najjar Syndrome. The company will start the clinical trials of these candidates in 2017 with products produced at the new facility.
• Momenta Pharmaceuticals ($MNTA) announced positive results from a Phase 3 clinical trial assessing M923. The treatment is designed for patients with moderate-to-severe plaque psoriasis. The study met its primary endpoint of demonstrating equivalence between M923 and HUMIRA as measured by the proportion of patients achieving PASI-75.

• Merck KGaA's ($MKGAF) Biologics License Application for the approval of avelumab has been accepted by the FDA under Priority Review for rare type of skin cancer. Priority Review status shortens the review clock to six months from the usual 10 months. Therefore, the decision should be out around June 1, 2017.
• ARIAD Pharmaceuticals' ($ARIA) received full approval from the FDA for its Iclusig (ponatinib) drug. The treatment is designed for adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML)

• Genetic Technologies ($GENE) inked an exclusive worldwide license agreement with The University of Melbourne for the development and commercialization of a novel colorectal cancer (CRC) risk assessment test. Both the parties will start an ongoing research collaboration use the University's expertise in SNP (single nucleotide polymorphism)-based risk assessment and risk model development.
• Omnicell ($OMCL) has agreed to acquire Ateb and its Canadian affiliate Ateb Canada Ltd. The transaction is expected to be worth nearly $41 million in cash, subject to adjustments. The transaction is likely to close this quarter. Ateb deals in providing pharmacy-based patient care solutions including medication synchronization.

 

• Mallinckrodt ($MNK) reported better than expected fourth quarter results. The company reported $2.04 in earnings per share while its revenue stood at $887.2 million.
• Forward Pharma ($FWP) reported its third quarter loss at $0.15 per share. Its cash and equivalents balance stood at $150.2 million.

• BioMarin Pharmaceuticals ($BMRN) receives rating downgrade from Barclays. Its new rating is Equal Weight and the price target is $105, down from $125.
• Johnson & Johnson ($JNJ) stock was downgraded to Equal Weight by Barclays. Its price target has been slashed from $130 to $125.

Gainers (% price change) Last Trade Change Mkt Cap
Kindred Healthcare, Inc.
KND (NYSE)
7.05 +0.50 (7.63%) 586.94M
Sucampo Pharmaceuticals
SCMP (NASDAQ)
17.15 +1.00 (6.19%) 800.98M
Alexion Pharmaceuticals
ALXN (NASDAQ)
125.59 +6.21 (5.20%) 28.29B
BioSpecifics Tech. Corp.
BSTC (NASDAQ)
49.85 +2.40 (5.06%) 338.18M
Bovie Medical Corporation
BVX (NYSE)
4.22 +0.20 (4.98%) 113.00M
Losers (% price change)
Amicus Therapeutics, Inc.
FOLD (NASDAQ)
6.51 -1.81 (-21.75%) 866.16M
Corcept Therapeutics Inc.
CORT (NASDAQ)
8.43 -0.66 (-7.26%) 926.82M
NewLink Genetics Corp
NLNK (NASDAQ)
11.46 -0.59 (-4.90%) 310.20M
Landauer Inc
LDR (NYSE)
49.85 -2.45 (-4.68%) 475.12M
United Therapeutics Corp.
UTHR (NASDAQ)
126.57 -6.17 (-4.65%) 5.30B
Most Actives (dollar volume)
UnitedHealth Group Inc
UNH (NYSE)
157.59 +5.48 (3.60%) 149.31B
Johnson & Johnson
JNJ (NYSE)
112.48 -0.65 (-0.57%) 303.32B
Pfizer Inc.
PFE (NYSE)
31.92 +0.38 (1.20%) 192.79B
Eli Lilly and Co
LLY (NYSE)
67.15 -0.05 (-0.07%) 72.07B
Merck & Co., Inc.
MRK (NYSE)
62.19 +0.39 (0.63%) 170.34B